{
  "docId": "019de076-b0fc-7764-be49-9cb0f9de8ba9",
  "docSlug": "ed8052d583ef5c8745075e02dbad124b",
  "documentTitle": "MAIA Biotechnology | Investor Presentation Deck | 31 slides",
  "authorId": "maia-biotechnology",
  "authorName": "MAIA Biotechnology",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 31,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "peer_benchmark",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "Data cut of ongoing study THIO-101 as of 13Nov2023.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b0fc-7764-be49-9cb0f9de8ba9/13",
  "deckHref": "/decks/019de076-b0fc-7764-be49-9cb0f9de8ba9",
  "deckJsonHref": "/decks/019de076-b0fc-7764-be49-9cb0f9de8ba9.json",
  "deckAnchorHref": "/decks/019de076-b0fc-7764-be49-9cb0f9de8ba9#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.03,
        "y": 0.96
      },
      "kind": "disclaimer",
      "text": "Note: All clinical data presented from 13Nov2023 data cut of ongoing study, THIO-101.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1242e1db-9f8d-4a95-bae1-756d8131e57a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.42,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "list",
      "text": "Overall, THIO sequenced with cemiplimab has been generally well-tolerated to date in a heavily pre-treated population, with the majority of Adverse Events (AEs) being Grade 1-2. Chemo (SOC): 70-80% incidence of Grade 3-5 side effect. Best dose: to date, 60% of patients in the 180mg/dose reported no related AEs. 3 out of 20 patients (15%) reported Grade 3 LFT increases, without clinical presentation; reverted to normal after treatment discontinuation. No patients reported Grade 4 AEs in the 180mg/dose. Of the 60 patients who received at least one dose of THIO, 5 subjects were recently enrolled with less than 1 full cycle of treatment and no AEs were entered in the database. They were removed from the safety analysis to not underestimate the AE incidence.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fbe15e15-dc18-483d-83e9-013874b256c8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.45,
        "x": 0.46,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "* https://www.cyramza.com/hcp/nsclc-treatment/revel-trial-safety",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3dc3178e-ab0a-4440-be89-12cb7088d215",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.55,
        "x": 0.43,
        "y": 0.15
      },
      "kind": "table",
      "text": "Treatment Related AEs | Cyramza + docetaxel (n=627) REVEL Study | THIO 180mg (n=20) | Grade 5 | 5.4% | | Grade 4 | 30% | | Grade 3 | 50% (Neutropenia: 49%, Febrile Neutropenia: 16%, Fatigue: 14%, Leukopenia: 14%) | 15% (LFT Elevations (no clinical presentation): 15%) | Any Grade | 613 (97.8%) | 8 (40%)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca52318a-1c24-406a-851f-f81e3236e0b4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.55,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "FAVORABLE SAFETY PROFILE",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0ef5c97d-ea97-4cf2-9543-7fc0204f711d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}